Abstract 3864
Background
Role of Tg levels as a biomarker in RAI-R DTC during MKI is unclear. Falling levels of Tg after starting MKI treatment has been previously reported, with a higher reduction in patients who achieve response. However, transient Tg oscillations are a common phenomenon during therapy without a clear correlation with progressive disease (PD). In the present study, we analyze the correlation between Tg oscillations and progression-free survival (PFS) in patients with RAI-R DTC during MKI treatment.
Methods
Thirty-seven consecutive patients were reviewed. Inclusion criteria were: pathology confirmed RAI-R DTC, age >18 years, MKI treatment in the first or second line and serial Tg determinations along with the follow-up. Variations in Tg levels during MKI treatment were evaluated. As exploratory hypothesis, we considered the “Tg elevation non-PD related”, defined as a significant elevation of Tg higher than 50% compared with previous measure, not related with PD by RECIST criteria, followed by a Tg reduction in a subsequent determination, in patients with an initial Tg reduction after starting MKI treatment.
Results
33 patients were included in the final analysis. Most MKI treatments were Sorafenib (44%), Lenvatinib (27%), Vandetanib (10%) and Axitinib (8%). Median duration of treatment was 15.5 months, and median PFS 20.2 months. Patients with any Tg levels reduction compared with baseline along MKI treatment showed a better PFS (23.5 vs. 3.6 months, p < 0.001). A Tg reduction >50% from baseline on the first month after starting MKI also had a benefit in PFS (27.7 vs. 14.2, p 0.02). 20.6% of cases had the nadir of Tg response beyond the first month of treatment. 34.4% of cases presented Tg elevation non-PD related along with follow-up (median number of elevations per patient: 2), with a better PFS compared with patients with other Tg oscillation patterns (29.9 vs. 15.5 months, p0.008).
Conclusions
Tg elevation non-PD related was associated with a better PFS compared with patients with other Tg variation patterns. Treatment with MKIs should not be stopped or changed based on Tg variations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Hernando Cubero: Speaker Bureau / Expert testimony: Eisai, Ipsen, Roche, Angelini Pharma; Travel / Accommodation / Expenses: Ipsen, Novartis, AAA, Roche, AstraZeneca, Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
1109 - First Canadian Interim Analysis from the Phase IIIb CompLEEment-1 Ribociclib + Letrozole HR+ HER2- Advanced Breast Cancer Trial
Presenter: Cristiano Ferrario
Session: Poster Display session 2
Resources:
Abstract
4401 - Real-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US
Presenter: Jonathan Kish
Session: Poster Display session 2
Resources:
Abstract
5876 - Palbociclib-Fulvestrant (PALBO-FUL) and Everolimus -Exemestane (EVE-EXE) for Second line Hormonal Treatment (HT) of Metastatic Breast Cancer (MBC) with Lobular Histology: a Propensity Score Matched Analysis of a Multicenter ‘Real-World’ Patients (pts) Series.
Presenter: Armando Orlandi
Session: Poster Display session 2
Resources:
Abstract
3587 - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
Presenter: E Dees
Session: Poster Display session 2
Resources:
Abstract
5696 - Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of ER+ Her2- Metastatic breast cancer (mBC)
Presenter: Sacha Howell
Session: Poster Display session 2
Resources:
Abstract
1475 - Alpelisib (ALP) + Fulvestrant (FUL) in Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2–Negative (HER2–) Advanced Breast Cancer (ABC): Subgroup Analysis by Presence of Visceral Metastasis (VM) in the SOLAR-1 Trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
2549 - Phase 1 Dose Escalation Study of a Selective Androgen Receptor Modulator RAD140 in Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) Breast Cancer (BC)
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3787 - A Phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours
Presenter: Binghe Xu
Session: Poster Display session 2
Resources:
Abstract
4835 - Phase-I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
Presenter: Huiping Li
Session: Poster Display session 2
Resources:
Abstract
5083 - Phase 2 study of DHP107 (Liporaxel®, oral paclitaxel) in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)
Presenter: Jin-Hee Ahn
Session: Poster Display session 2
Resources:
Abstract